DEBAMESTROCEL
UNII GPC34QP6X6

Substance Identification & Data

This profile provides standardized clinical and technical data for Debamestrocel, uniquely identified by the FDA Unique Ingredient Identifier (UNII) GPC34QP6X6.

Technical mappings include the Chemical Abstracts Service (CAS) Registry Number N/A and the RxNorm Concept ID (RxCUI) N/A. Explore the sections below for detailed nomenclature and a complete directory of NDC-listed products containing this ingredient.

FDA UNII Code

GPC34QP6X6

CAS Registry Number

N/A

RxNorm Concept ID

N/A

Detailed Substance Profile

Preferred Name

DEBAMESTROCEL

Official standardized name for this substance within the FDA UNII nomenclature system.

NCI Thesaurus

C190756

National Cancer Institute reference terminology for clinical and research data.

INN ID

12415

Sequential identifier assigned via the WHO International Nonproprietary Name program.

USAN ID

JK-263

Identifier assigned by the United States Adopted Names Council.

Substance Type

structurallyDiverse

ISO 11238 classification category (e.g., Chemical, Polymer, Protein).

ITIS TSN

180092

Taxonomic Serial Number for species identified in the Integrated Taxonomic Information System.

NCBI Taxonomy

9606

Unique numeric identifier used to specify biological species in the NCBI database.

Synonyms and Nomenclature

This section provides a complete list of nomenclature and identifier mappings for Debamestrocel. Identifiers are organized into official regulatory terms, commercial trade names, and technical systematic synonyms used to ensure accurate identification across clinical pharmaceutical databases, regulatory filings, and electronic health records.

FDA Official Name

DEBAMESTROCEL

Common Names & Synonyms

AUTOLOGOUS MESENCHYMAL STROMAL CELLS (MSC) SECRETING NEUROTROPHIC FACTORS (NTF)

AUTOLOGOUS MESENCHYMAL STROMAL CELLS SECRETING NEUROTROPHIC FACTORS

AUTOLOGOUS MSC-NTF

DEBAMESTROCEL [INN]

DEBAMESTROCEL [USAN]

THE MSC-NTF CELLS ARE MESENCHYMAL STEM CELLS (MSC) SECRETING NEUROTROPHIC FACTORS. THE AUTOLOGOUS MSC ARE ISOLATED FROM THE MONONUCLEAR FRACTION OF THE PATIENT'S OWN BONE MARROW (BM), PROPAGATED EX-VIVO IN A XENO-FREE GROWTH MEDIUM AND INDUCED TO DIFFERENTIATE INTO MSCS SECRETING HIGH LEVELS OF NEUROTROPHIC FACTORS (NTF) IN A PROPRIETARY DEFINED DIFFERENTIATION MEDIUM. ONCE PROPAGATED TO A LARGE NUMBER OF CELLS, MSC ARE HARVESTED AND CRYOPRESERVED FOR PROVIDING FRESH MSC-NTF CELLS FOR EACH REPEATED DOSING CYCLE. IN ADVANCE OF EACH TREATMENT CYCLE MSC ARE THAWED PROPAGATED AND INDUCED TO DIFFERENTIATE INTO MSC-NTF CELLS WHICH ARE ADMINISTERED TO THE PATIENT

Brand / Trade Names

NUROWN

External Clinical & Regulatory Resources

Previous UNIIGPB8B78FYR

Next UNIIGPC6FXQ24V